Showing results (341-350 of 373) with videos related to

Sort By:
Pageof 38
Oncotarget|February 18, 2016
Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutationNayoung Kim, Ahye Cho, Hideo Watanabe, et al.
JAMA Oncology|July 7, 2022
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical TrialHee Kyung Ahn, Sung Hoon Sim, Koung Jin Suh, et al.
Scientific Reports|March 29, 2017
A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2- early breast cancerGyungyub Gong, Mi Jeong Kwon, Jinil Han, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 2015
Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapyHye Won Lee, Jung-Il Lee, Se Jeong Lee, et al.
BMC Cancer|May 9, 2024
Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09Sun Young Kim, Jee Hyun Kim, Tae-Yong Kim, et al.
Cancers|June 19, 2020
Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted CancerJooseok Kim, Kyung Eui Park, Yoo-Seong Jeong, et al.
Journal for Immunotherapy of Cancer|October 20, 2020
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purityTae Hee Hong, Hongui Cha, Joon Ho Shim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 13, 2016
Comprehensive Characterization of Oncogenic Drivers in Asian Lung AdenocarcinomaShiyong Li, Yoon-La Choi, Zhuolin Gong, et al.
Journal for Immunotherapy of Cancer|October 31, 2025
Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitorYeong Hak Bang, Geun-Ho Park, Jin Woo Oh, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 19, 2025
Perioperative Pembrolizumab for Locally Advanced Thymic Epithelial Tumors: A Single-Arm, Phase 2 TrialYeong Hak Bang, Jae Myoung Noh, Boram Lee, et al.
Pageof 38